	US 11,957,749 B2
	Hepatitis B immunization regimen and compositions
Virginia Ammendola, Rome (IT); Babak Bayat, Rixensart (BE); Clarisse Lorin, Rixensart (BE); Ventzislav Bojidarov Vassilev, Rixensart (BE); and Alessandra Vitelli, Rome (IT)
Assigned to GlaxoSmithKline Biologicals SA, (BE)
Appl. No. 16/772,194
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Dec. 14, 2018, PCT No. PCT/EP2018/085086 § 371(c)(1), (2) Date Jun. 12, 2020, PCT Pub. No. WO2019/115817, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 1721069 (GB), filed on Dec. 15, 2017.
Prior Publication US 2021/0154290 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61K 39/39 (2006.01); A61P 31/20 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/292 (2013.01) [A61K 39/39 (2013.01); A61P 31/20 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/57 (2013.01); C07K 2319/40 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24143 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10134 (2013.01)]

9 Claims

1. An immunogenic composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide encoding a hepatitis B virus core antigen (HBc), wherein the polynucleotides encoding HBs and HBc are separated by a polynucleotide encoding the 2A cleaving region of the foot and mouth disease virus (FMDV).